This automated computerized image analyzer just got approval in Japan as a PRIMARY screener of pap tests. It previously had approval as a rescreener after primary screening by a cytotechnologist. It also has FDA approval here in the US as a rescreener for quality control. Since indications are that this is better than human screeners, perhaps approval as a primary screener will be following in the US.
At this time, the company seems to be placing instruments here and overseas at a decent pace. But I have not figured out yet how to value this company. How much revenue per slide is there. How much useage is there so far and what is the pace. I think their nearest competitor is papnet, but from what I can tell, neopath is a bit ahead in technology and way ahead in placements. Also, they have some kind of alliance? with cytyc (thinprep-which I think will be the new standard for pap tests).
The advantages are better accuracy and sensitivity. The costs I'm guessing are lower. Disadvantages are cytotechs will lose many jobs in all probability (times are tough).
Anyone have knowledge? |
